Jump to main content
Jump to site search
Book cover

Emerging Drugs and Targets for Multiple Sclerosis Editor: Ana Martinez



Buy hardback £159.00 *
Add to pick and choose £477.00
* Exclusive of taxes
This book contains 333 pages.
Print publication date: 28 Jun 2019
Copyright year: 2019
Print ISBN: 978-1-78801-450-2
PDF eISBN: 978-1-78801-607-0
ePub eISBN: 978-1-78801-806-7

About this book

Multiple sclerosis (MS) is a complex disease with a presumed autoimmune aetiology and few current effective treatments. Disease modifying therapies focus on the altering the natural course of relapsing and remitting MS, targeting the inflammatory response. Other targets involve tacking the cause of the disease – demyelination of axons through remyelination therapies. Due to several recent breakthroughs in the understanding of the pathophysiology of MS new targets for remyelination and immunomodulation are rapidly emerging. This book provides a comprehensive overview of drug discovery and development for the molecular basis of the disease, from new targets to drugs currently in clinical development, cellular and animal disease models to biomarkers for diagnosis and assessment in clinical trials.

Emerging Drugs and Targets for Multiple Sclerosis

is an ideal reference for any student or researcher interested in drug development for neurodegenerative diseases, autoimmune diseases and MS in particular.

From the book series:
Drug Discovery